All In Biotech

Drug Trial Radar · NCT05393037

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 313 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

313

Actual

Start

Jul 13, 2022

Primary completion

Jul 13, 2023

Study completion Jan 25, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease caused by the serotypes in the vaccine.

Conditions

  • Pneumococcal Disease

Interventions

  • V116Biological

    Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

  • PlaceboBiological

    Saline in each 0.5 mL sterile solution

  • PCV15Biological

    Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension

  • PPSV23Biological

    Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

  • PCV15 - Part BBiological

    Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Solicited Injection-site AEs From Day 1 Through Day 5 Postvaccination in Part ATime frame: Up to 5 days after each vaccination in Part A
  2. Percentage of Participants With Solicited Systemic AEs From Day 1 Through Day 5 Postvaccination in Part ATime frame: Up to 5 days after each vaccination in Part A
  3. Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through the Duration of Participation in Part ATime frame: Up to 194 days in Part A
  4. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116Time frame: Up to 114 days

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • Pueblo Family Physicians ( Site 0014)

    Phoenix, Arizona

  • Whitman-Walker Institute ( Site 0009)

    Washington D.C., District of Columbia

  • Midway Immunology and Research Center ( Site 0003)

    Ft. Pierce, Florida

  • Orlando Immunology Center ( Site 0004)

    Orlando, Florida

  • KC CARE Health Center ( Site 0013)

    Kansas City, Missouri

  • North Texas Infectious Diseases Consultants, P.A ( Site 0001)

    Dallas, Texas

  • Texas Center for Infectious Disease Associates ( Site 0011)

    Fort Worth, Texas

  • Insituut voor tropische Geneeskunde ( Site 0501)

    Antwerp, Belgium

  • CHU Saint-Pierre ( Site 0500)

    Brussels, Bruxelles-Capitale, Region de, Belgium

  • Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 0101)

    Temuco, Araucania, Chile

  • Universidad San Sebastian - Providencia ( Site 0111)

    Providencia, Region M. de Santiago, Chile

  • Universidad de Chile - Hospital Clínico Universidad de Chile ( Site 0107)

    Santiago, Region M. de Santiago, Chile

  • Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0601)

    Paris, France

  • Hôpital Saint-Louis ( Site 0600)

    Paris, Île-de-France Region, France

  • Josha Research ( Site 0900)

    Bloemfontein, Free State, South Africa

  • Perinatal HIV Research Unit (PHRU)-Adult Treatment and Research ( Site 0906)

    Johannesburg, Gauteng, South Africa

  • Right To Care Research - Esizayo ( Site 0904)

    Johannesburg, Gauteng, South Africa

  • Be Part Yoluntu Centre ( Site 0902)

    Paarl, Western Cape, South Africa

  • Research Institute for Health Sciences-Research Institute for Health Sciences Building 1 ( Site 1101

    Chiang Mai, Thailand

  • Faculty of Medicine Siriraj Hospital-Preventive and social ( Site 1100)

    Bangkok, Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.